Parc Tauli Sabadell University Hospital
Sabadell, Barcelona, 08208, Spain
NCT Number: NCT01850199
Gestational diabetes, diabetes diagnosed during pregnancy, affects 8.8% of pregnancies in Spain that means more than 40,000 women per year. This prevalence is based on the National Diabetes Data Group criteria, previous to the 4th workshop on Gestational Diabetes (1998), but, if the new diagnosis criteria proposed by the International Associations of Diabetes and Pregnancy Study Groups, based on the most important study never made before on this topic, prevalence would increase to the double. When a women is diagnosed, the risk of complications for her and the child increases and, therefore, she has to start an specific diet and frequent visits to the diabetes center in order to check that glucose values do not exceed 95 mg/dl before or 140 mg/dl 1-hour after meals. In other case, she should start insulin treatment. Our project is aimed to develop intelligent tools based on neuro-diffuse techniques and integrated in a telemedicine system that allows control of gestational diabetes automatically, guaranteeing glucose control objectives consecution and avoiding face-to-face visits to the health care center. Furthermore, educational and motivation tools for a healthy behaviour will be included. At the end of the study efficacy and security about insulin management will be compare with the recommendations proposed by the diabetes team and data about direct and indirect costs will be calculated. The investigators anticipate that the smart telemedicine system can allow us to detect high blood glucose values earlier than in-person scheduled visits.
Looking for future studies?
Notify Me18 year–46 year
Female
Interventional
Not applicable
Sabadell, Barcelona, 08208, Spain
This study aims to evaluate the safety and usability of a telemedicine system which includes intelligent tools for blood glucose analysis and supporting routine clinical monitoring carried out by nurses and endocrinologists.
Type of study: Prospective, controlled, randomized (2:1) Participants: pregnant women diagnosed with gestational diabetes according to the National Diabetes Data Group criteria between 14 and 34 weeks of gestation. Patients with suspected clinical diagnosis of type 1 or type 2 diabetes will be excluded.
In addition to the signed acceptance to participate in the study, requirements are:
Methodology of the study: Once signed consent for participation the patient will be randomized either to continue regularly scheduled visits (33% chance) or to use the Telemedicine system (66% chance). The randomization will be done using a system of allocation based on random numbers. The SINEDiE system includes:
All warnings are also reported as an email to the endocrinologist and nurse
Variables:
Expected duration of the study: 6 months Number of patients included 20 patients
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.
Usual care will be provided, including face-to-face visits
Time frame: From inclusion to delivery (estimate average period 10±2 weeks)
Blood glucose data downloaded from the glucometer will allow to obtain the main outcome.
Time frame: From inclusion to delivery From inclusion to delivery (estimate average period 10±2 weeks)
Corporacion Parc Tauli
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07336914
Diabetes Mellitus, Diabetes, Gestational
Peshawar, Khyber Pakhtunkhwa, Pakistan
View Trial DetailsNCT06127823
Diabetes Mellitus, Diabetes, Gestational
Herlev, Denmark
View Trial DetailsNCT04724330
Body Weight, Body Weight Changes
Baltimore, Maryland, United States
View Trial DetailsNCT06556927
Anxiety, Anxiety Disorders
Kırklareli, Turkey (Türkiye)
View Trial Details